01Tempest Therapeutics reported Q3 EPS of -$0.21, beating estimates of -$0.32 by $0.11 per share on November 13, 2026.
02The company's stock trades at $0.34 with a market capitalization of $14.1 million.
03The 34% earnings beat represents a notable deviation from consensus, though the company remains unprofitable.
04Recent quarterly results show improvement from Q1's -$0.50 EPS, but mixed performance versus estimates across the last four quarters.
Earnings Results
Tempest Therapeutics (NASDAQ:TPST) reported quarterly earnings results on November 13, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $-0.21, beating the consensus estimate of $-0.32 by $0.11 per share. Revenue came in at , meeting the estimate of .
Company Overview
Tempest Therapeutics's stock moved following the earnings release. The stock currently trades at $0.34 with a market capitalization of $14.1M.
Tempest Therapeutics's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
The 34% beat relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Tempest Therapeutics should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.